|PF-05212384 (PKI-587)PI3Kα, PI3Kγ and mTOR inhibitor|
Sample solution is provided at 25 µL, 10mM.
Publications citing ApexBio Products
Related Compound Libraries
|Description||PF-05212384 (PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ and mTOR with IC50 values of 0.4 nM, 5.4 nM and 1.6 nM, respectively.|
|IC50||0.4 nM||1.6 nM||5.4 nM|
|Cas No.||1197160-78-3||SDF||Download SDF|
|Solubility||Limited solubility||Storage||Store at -20°C|
|General tips||For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.|
|Shipping Condition||Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
PF-05212384 is an inhibitor of PI3K/mTOR with IC50 values of 0.4nM, 6nM, 8nM, 6nM and 1.4nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ and mTOR, respectively .
PF-05212384 is a pan-PI3K/mTORinhibitor and shows to be highly selective for PI3K and mTOR. Besides the wt P13K, PF-05212384 can also inhibit mutant P13K with IC50 values of 0.6nM for both H1047R and E545K mutants. In cellular assay, PF-05212384 potently inhibits tumor growth in MDA-361 and PC3-MM2 cell lines with IC50 values of 4nM and 13.1nM, respectively. Meanwhile, PF-05212384 suppresses the phosphorylation of PI3K/mTOR signaling pathway proteins in cells. It inhibits the phosphorylation of Akt as well as the Akt effector proteins including GSK3 kinase, ENOS and PRAS 40. Moreover, PF-05212384 has potent anti-tumor activity in a variety of xenograft models including H1975, BT474, HCT116, H1975 and U87MG [1, 2]
 Venkatesan A M, Dehnhardt C M, Delos Santos E, et al. Bis (morpholino-1, 3, 5-triazine) derivatives: potent adenosine 5′-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. Journal of medicinal chemistry, 2010, 53(6): 2636-2645.
 Mallon R, Feldberg L R, Lucas J, et al. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. Clinical Cancer Research, 2011, 17(10): 3193-3203.